Zephrex-D tv commercials
TV spots
TV commercials Zephrex-D
Zephrex-D is an over-the-counter medication for the relief of nasal congestion and allergies. The Zephrex-D TV spot, 'Science Educator,' is a creative advertisement that features a science educator explaining the difference between Zephrex-D and other allergy medications.The ad begins with a science...
What kind of company is Zephrex-D?
Zephrex-D: IntroductionZephrex-D is a nasal decongestant marketed as a solution to the growing methamphetamine problem in the US. It was developed by Westport Pharmaceuticals, a St. Louis-based company, and was designed to be tamper-resistant to prevent its use in illicit drug production.
Zephrex-D as a Meth-Fighting MedicationUnlike other cold and allergy medications containing pseudoephedrine (PSE), Zephrex-D uses a patented formula and technology to prevent its use in making methamphetamine. The drug is marketed as a safer alternative compared to other cold and allergy medications containing PSE, which have traditionally been a key ingredient in making meth.
Zephrex-D’s DevelopmentPrior to the development of Zephrex-D, Westport Pharmaceuticals worked with the University of Missouri to create a tamper-resistant form of PSE that would be difficult to convert into meth. This was achieved by incorporating a novel polymer matrix that makes it more difficult for meth producers to extract the PSE. Zephrex-D was quickly adopted by major pharmacies across the country in an effort to stop the spread of meth production.
Company Behind Zephrex-DWestport Pharmaceuticals, LLC, the company behind the development of Zephrex-D, was founded in 2008 and is based in St. Louis, Missouri. The company’s mission is to develop effective drugs that can be safely and responsibly used to address important public health issues. Besides Zephrex-D, Westport Pharmaceuticals is also a manufacturer of Nexafed, another tamper-resistant PSE medication designed to combat the production of methamphetamine.
Importance of Zephrex-DThe threat posed by illegal production and use of methamphetamine has been a growing concern in many countries for decades. The development of Zephrex-D has provided a proactive solution to the problem by significantly reducing the use of PSE in meth labs. As a result, measures like purchasing restrictions are not necessary, and patients can continue to have access to the medication they need.
In conclusion, Zephrex-D has been a breakthrough drug in combating the production of methamphetamine. Its development by Westport Pharmaceuticals has contributed to reducing the use of PSE in meth labs, providing a viable and safe alternative to traditional PSE-containing cold and allergy medications.
